Legislators in New Hampshire have been scrambling to clarify new minimum training requirements for workers in assisted living and other settings caring for residents with dementia after a bill with the requirements was tucked into the state budget and passed even though it “wasn’t ready for prime time.”
The appropriation bill signed into law Friday contains a $350 million increase for Alzheimer’s and dementia research funding at the National Institutes of Health. The increase brings total annual NIH funding for Alzheimer’s and dementia research to $2.8 billion.
Two Ohio lawmakers have introduced legislation that would require first responders to receive Alzheimer’s disease training.
An Office of Alzheimer’s Disease would be created in Florida under a bill introduced Monday in the state House of Representatives by Rep. Matt Willhite, a Democrat, and Rep. Scott Plakon, a Republican.
An apple a day might keep the doctor away. But a diet rich in olive oil could prevent cognitive impairment.
A “better business model for the diagnosis and care of persons with Alzheimer’s disease” needs to be created, Jason Karlawish, M.D., said Wednesday at a Senate Finance Committee Subcommittee on Health hearing.
A person-centered approach to memory care led to the reduced or discontinued use of off-label antipsychotic medications in more than half of the residents of 53 long-term care communities, including assisted living communities, who participated in a study, the results of which were announced last week.
Dec. 5 is deadline to comment on Labor Department’s proposed fluctuating workweek method of computing overtime … Citing eagerness from states, CMS announces plans to issue guidance on Medicaid block grants … Older adults with Alzheimer’s who take antipsychotics hospitalized more frequently
Assisted living will figure squarely into the work of a new Alzheimer’s Disease and Related Dementias Task Force created in the Buckeye State under S.B. 24, which Ohio Gov. Mike DeWine (R) has signed into law.
Subsidiaries of pharmaceutical company Allergan will pay $750 million to resolve a class action lawsuit from a group of direct purchasers of Alzheimer’s drug Namenda (memantine).
